Çocuk ve Ergen Psikofarmakolojisinin Temel İlkeleri
Özet
Çocuk ve ergen psikofarmakolojisi, 1937'den bu yana ilerleme kaydetmiş olsa da klinik uygulamalar ile araştırmalar arasında, özellikle ilaçların uzun vadeli etkileri ve güvenilirliği konusunda belirgin boşluklar barındırmaktadır. Psikotrop ajanların kullanımı son yirmi yılda ciddi oranda artış göstermiş olup, tedavi sürecinde ilk adım her zaman kapsamlı bir tanısal değerlendirme ile psikososyal formülasyonun yapılmasıdır. Psikotik olmayan bozukluklarda öncelikle farmakolojik olmayan müdahaleler ve kombinasyon tedavileri tercih edilirken, ilaç seçiminde çocuğun yaşına uygun kanıt düzeyi (Tip I-V) ve ilaç düzenleme kurumlarının onayları dikkate alınmaktadır. Çocukların büyüme süreçleri; daha büyük karaciğer-böbrek ağırlığı, yüksek dağılım hacmi ve hızlı eliminasyon gibi farmakokinetik farklılıklara yol açarak mg/kg başına daha yüksek doz ihtiyacı veya sık dozlama gerektirebilir. Gelişimsel süreç aynı zamanda nörotransmiter reseptör yoğunluğunu etkileyerek ilaçların etkinliğini ve yan etki profillerini (örneğin antidepresanların intihar düşüncesini artırma riski veya antipsikotiklerin metabolik yan etkileri) yetişkinlerden farklı kılmaktadır. İlaçların etkinliği semptom takibi, etki boyutu ve NNT (tedavi için gereken sayı) gibi ölçütlerle değerlendirilirken, stimülanların fiziksel büyümede gecikmeye yol açabilmesi gibi gelişimsel döneme özgü kronik güvenlik endişeleri yakından izlenmelidir. Klinisyenlerin tedaviyi düşük dozda başlatması, çoklu bilgi kaynaklarından yararlanması, hedef semptomları izlemesi ve sonlandırma aşamasında kademeli azaltma planlaması başarılı bir farmakoterapi protokolünün temel ilkelerini oluşturmaktadır.
The field of child and adolescent psychopharmacology has progressed since 1937, yet distinct gaps remain between clinical practices and research, particularly regarding the long-term effects and safety of medications. The use of psychotropic agents has increased significantly over the past two decades, and the crucial initial step in the treatment process is always to conduct a comprehensive diagnostic assessment along with a psychosocial formulation. For non-psychotic disorders, non-pharmacological interventions and combination therapies are preferred, while drug selection is guided by the level of evidence (Types I-V) appropriate for the child's age and approvals from regulatory agencies. Developmental processes in children lead to pharmacokinetic differences, such as larger liver and kidney weights relative to body size, higher volume of distribution, and faster elimination, which may necessitate higher doses per mg/kg or more frequent dosing. The developmental process also alters neurotransmitter receptor density, making drug efficacy and side effect profiles (such as the risk of antidepressants increasing suicidal ideation or the metabolic side effects of antipsychotics) different from those in adults. While drug efficacy is evaluated through symptom monitoring, effect size, and NNT (number needed to treat), developmental-specific chronic safety concerns, such as stimulants causing delays in physical growth, must be closely monitored. It is fundamental for clinicians to initiate treatment at low doses, utilize multiple informational sources, target specific symptoms, and plan gradual titration during the discontinuation phase for a successful pharmacotherapy protocol.
Referanslar
Vitiello B, Davico C. Twenty years of progress in paediatric psychopharmacology: accomplishments and unmet needs. Evid Based Ment Health. 2018;21(4):e10–e10.
Group MTAC. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073–86.
Group MTAC. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113(4):762–9.
Chen LY, Crum RM, Strain EC. Prescriptions, nonmedical use, and emergency department visits involving prescription stimulants. J Clin Psychiatry. 2016;77(3):15331.
Aparasu RR, Bhatara V. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003–2004. Curr Med Res Opin. 2007;23(1):49–56.
Vitiello B. Combined cognitive-behavioural therapy and pharmacotherapy for adolescent depression. CNS Drugs. 2009;23(4):271–80.
Gray JA, Chambers LW. Evidence-based healthcare: how to make health policy & management decisions. Can Med Assoc J. 1997;157(11):1598.
Emslie GJ, Kennard BD, Mayes TL. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. American Journal of Psychiatry. 2008;165(4):459–67.
Network RU on PPA. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry. 2005;162(7):1361–9.
Lorberg B, Davico C, Martsenkovskyi D, Vitiello B. Principles in using psychotropic medication in children and adolescents. IACAPAP e-Textbook of Child and Adolescent Mental Health (pp A7) International Association for Child and Adolescent Psychiatry and Allied Professions. 2019;
Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571–90.
SALLEE FR, DeVANE CL, FERRELL RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol. 2000;10(1):27–34.
Daviss WB, Perel JM, Rudolph GR. Steady-state pharmacokinetics of bupropion SR in juvenile patients. J Am Acad Child Adolesc Psychiatry. 2005;44(4):349–57.
Axelson DA, Perel JM, Birmaher B. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1037–44.
Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46(4):281–90.
Findling RL, Kauffman RE, Sallee FR. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol. 2008;28(4):441–6.
Thyssen A, Vermeulen A, Fuseau E. Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet. 2010;49(7):465–78.
Findling RL, Landersdorfer CB, Kafantaris V. First-dose pharmacokinetics of lithium carbonate in children and adolescents. J Clin Psychopharmacol. 2010;30(4):404.
Chugani DC, Muzik O, Juhász C. Postnatal maturation of human GABAA receptors measured with positron emission tomography. Ann Neurol. 2001;49(5):618–26.
Hazell P, O’connell D, Heathcote D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. Bmj. 1995;310(6984):897–901.
Correll CU, Manu P, Olshanskiy V. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–73.
Stone M, Laughren T, Jones ML. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. Bmj. 2009;339.
Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332–9.
Greenhill L, Kollins S, Abikoff H. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1284–93.
King BH, Hollander E, Sikich L. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66(6):583–90.
McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107–25.
Birmaher B, Brent D, Issues AWG on Q. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1503–26.
Kendall T, Taylor E, Perez A. Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance. Bmj. 2008;337.
Pliszka S, Issues AWG on Q. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.
Middleton H, Shaw I, Hull S. NICE guidelines for the management of depression. Vol. 330, Bmj. British Medical Journal Publishing Group; 2005. p. 267–8.
Swanson JM, Kraemer HC, Hinshaw SP. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40(2):168–79.
Vitiello B, Davico C. Twenty years of progress in paediatric psychopharmacology: accomplishments and unmet needs. Evid Based Ment Health. 2018;21(4):e10–e10.
Kennard BD, Silva SG, Tonev S. Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry. 2009;48(2):186–95.
Greenhill LL, Swanson JM, Vitiello B. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40(2):180–7.
March JS, Silva S, Petrycki S. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007;64(10):1132–44.
Team POCDTSP. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004;292(16):1969–76.
Bridge JA, Iyengar S, Salary CB. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683–96.
Venekamp RP, Sanders SL, Glasziou PP. Antibiotics for acute otitis media in children. Cochrane database of systematic reviews. 2015;(6).
Vitiello B, Emslie G, Clarke G. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. J Clin Psychiatry. 2010;71(3):10732.
Findling RL, Johnson JL, McClellan J. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry. 2010;49(6):583–94.
Ansorge MS, Zhou M, Lira A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science (1979). 2004;306(5697):879–81.
Vitiello B, Riddle MA, WALKUP JT. How can we improve the assessment of safety in child and adolescent psychopharmacology? J Am Acad Child Adolesc Psychiatry. 2003;42(6):634–41.
Swanson JM, Elliott GR, Greenhill LL. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015–27.
Díez-Suárez A, Vallejo-Valdivielso M, Marín-Méndez JJ. Weight, height, and body mass index in patients with attention-deficit/hyperactivity disorder treated with methylphenidate. J Child Adolesc Psychopharmacol. 2017;27(8):723–30.
Gould MS, Walsh BT, Munfakh J lou. Sudden death and use of stimulant medications in youths. American Journal of Psychiatry. 2009;166(9):992–1001.
Schelleman H, Bilker WB, Strom BL. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127(6):1102–10.
Cooper WO, Habel LA, Sox CM. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine. 2011;365(20):1896–904.
Vitiello B, Elliott GR, Swanson JM. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. American Journal of Psychiatry. 2012;169(2):167–77.
Vitiello B. Long-term effects of stimulant medications on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11(1):25–34.
Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Vol. 165, American Journal of Psychiatry. Am Psychiatric Assoc; 2008. p. 553–5.
Biederman J, Monuteaux MC, Spencer T. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. American Journal of Psychiatry. 2008;165(5):597–603.
Wilens TE, Adamson J, Monuteaux MC. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008;162(10):916–21.
